Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Up 7.4% – Time to Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price shot up 7.4% during trading on Wednesday . The company traded as high as $78.72 and last traded at $78.72. 352 shares were traded during mid-day trading, a decline of 56% from the average session volume of 793 shares. The stock had previously closed at $73.28.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ZLDPF shares. Wells Fargo & Company upgraded Zealand Pharma A/S to a “strong-buy” rating in a report on Thursday, July 24th. Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Five analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Zealand Pharma A/S Trading Up 7.4%

The firm has a fifty day moving average of $72.72 and a 200 day moving average of $65.69. The firm has a market capitalization of $5.59 billion, a PE ratio of 5.53 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.08 and a current ratio of 15.09.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). The firm had revenue of $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. Equities research analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.